Acasti Pharma Total Current Liabilities 2014-2024 | GRCE
Acasti Pharma total current liabilities from 2014 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Acasti Pharma Annual Total Current Liabilities
(Millions of US $) |
| 2024 |
$2 |
| 2023 |
$3 |
| 2022 |
$3 |
| 2021 |
$2 |
| 2020 |
$7 |
| 2019 |
$14 |
| 2018 |
$5 |
| 2017 |
$2 |
| 2016 |
$1 |
| 2015 |
$1 |
| 2015 |
$ |
| 2014 |
$1 |
| 2014 |
$ |
| 2013 |
$2 |
| 2013 |
$ |
Acasti Pharma Quarterly Total Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$3 |
| 2024-03-31 |
$2 |
| 2023-12-31 |
$2 |
| 2023-09-30 |
$1 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$3 |
| 2022-12-31 |
$3 |
| 2022-09-30 |
$4 |
| 2022-06-30 |
$4 |
| 2022-03-31 |
$3 |
| 2021-12-31 |
$3 |
| 2021-09-30 |
$4 |
| 2021-06-30 |
$2 |
| 2021-03-31 |
$2 |
| 2020-12-31 |
$2 |
| 2020-09-30 |
$4 |
| 2020-06-30 |
$6 |
| 2020-03-31 |
$7 |
| 2019-12-31 |
$11 |
| 2019-09-30 |
$12 |
| 2019-06-30 |
$13 |
| 2019-03-31 |
$14 |
| 2018-12-31 |
$10 |
| 2018-09-30 |
$10 |
| 2018-06-30 |
$8 |
| 2018-03-31 |
$5 |
| 2017-12-31 |
$4 |
| 2017-09-30 |
$3 |
| 2017-06-30 |
$1 |
| 2017-02-28 |
$2 |
| 2016-11-30 |
$1 |
| 2016-08-31 |
$1 |
| 2016-05-31 |
$1 |
| 2016-03-31 |
$1 |
| 2016-02-29 |
|
| 2015-12-31 |
$1 |
| 2015-09-30 |
$1 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$2 |
| 2014-06-30 |
$2 |
| 2014-03-31 |
$1 |
| 2014-02-28 |
|
| 2013-12-31 |
$5 |
| 2013-09-30 |
$4 |
| 2013-06-30 |
$3 |
| 2013-03-31 |
$2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
